Latest Lucentis Stories
INCLINE VILLAGE, Nev., June 9, 2011 /PRNewswire/ -- PDL BioPharma, Inc.
INCLINE VILLAGE, Nev., June 1, 2011 /PRNewswire/ -- PDL BioPharma, Inc.
SAN MATEO, Calif., May 16, 2011 /PRNewswire/ -- On April 28, 2011 the New England Journal of Medicine released highly anticipated one-year results of the ongoing "Comparisons of Age-Related Macular Degeneration Treatments Trials" (CATT). AlphaDetail, Inc., a leader in global ophthalmology primary market research and influence network mapping, has conducted its latest AlphaPulse(TM) survey with 120 Ophthalmologists to gauge their reactions on the heels of this important news. Amy Tsang, a...
Researchers are reporting results from the first year of a two-year clinical trial that Avastin, a drug approved to treat some cancers and that is commonly used off-label to treat age-related macular degeneration (AMD), is as effective as the Food and Drug Administration-approved drug Lucentis for the treatment of AMD.
INCLINE VILLAGE, Nev., Dec. 1, 2010 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc.
Age-related macular degeneration (AMD) is the leading cause of blindness for people over fifty.
Researchers from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have conducted a study that failed to show a difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD).
- an ornament or knob in the shape of a flower